Patents by Inventor Pierre E. Rollin

Pierre E. Rollin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10428314
    Abstract: Compositions and methods including and related to the Ebola Bundibugyo virus (EboBun) are provided. Compositions are provided that are operable as immunogens to elicit and immune response or protection from EboBun challenge in a subject such as a primate. Inventive methods are directed to detection and treatment of EboBun infection.
    Type: Grant
    Filed: August 28, 2017
    Date of Patent: October 1, 2019
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Jonathan S. Towner, Stuart T. Nichol, James A. Comer, Thomas G. Ksiazek, Pierre E. Rollin
  • Publication number: 20180002675
    Abstract: Compositions and methods including and related to the Ebola Bundibugyo virus (EboBun) are provided. Compositions are provided that are operable as immunogens to elicit and immune response or protection from EboBun challenge in a subject such as a primate. Inventive methods are directed to detection and treatment of EboBun infection.
    Type: Application
    Filed: August 28, 2017
    Publication date: January 4, 2018
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Serv
    Inventors: Jonathan S. Towner, Stuart T. Nichol, James A. Comer, Thomas G. Ksiazek, Pierre E. Rollin
  • Patent number: 9790473
    Abstract: Compositions and methods including and related to the Ebola Bundibugyo virus (EboBun) are provided. Compositions are provided that are operable as immunogens to elicit and immune response or protection from EboBun challenge in a subject such as a primate. Inventive methods are directed to detection and treatment of EboBun infection.
    Type: Grant
    Filed: April 23, 2015
    Date of Patent: October 17, 2017
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Jonathan S. Towner, Stuart T. Nichol, James A. Comer, Thomas G. Ksiazek, Pierre E. Rollin
  • Publication number: 20150218525
    Abstract: Compositions and methods including and related to the Ebola Bundibugyo virus (EboBun) are provided. Compositions are provided that are operable as immunogens to elicit and immune response or protection from EboBun challenge in a subject such as a primate. Inventive methods are directed to detection and treatment of EboBun infection.
    Type: Application
    Filed: April 23, 2015
    Publication date: August 6, 2015
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Serv
    Inventors: Jonathan S. Towner, Stuart T. Nichol, James A. Comer, Thomas G. Ksiazek, Pierre E. Rollin
  • Publication number: 20120251502
    Abstract: Compositions and methods including and related to the Ebola Bundibugyo virus (EboBun) are provided. Compositions are provided that are operable as immunogens to elicit and immune response or protection from EboBun challenge in a subject such as a primate. Inventive methods are directed to detection and treatment of EboBun infection.
    Type: Application
    Filed: October 26, 2009
    Publication date: October 4, 2012
    Applicant: The Government of the US as Represented by the Secretary of the Dept. of health
    Inventors: Jonathan S. Towner, Stuart T. Nichol, James A. Comer, Thomas G. Ksiazek, Pierre E. Rollin
  • Patent number: 7776521
    Abstract: Disclosed herein is a newly isolated human coronavirus (SARS-CoV), the causative agent of severe acute respiratory syndrome (SARS). Also provided are the nucleic acid sequence of the SARS-CoV genome and the amino acid sequences of the SARS-CoV open reading frames, as well as methods of using these molecules to detect a SARS-CoV and detect infections therewith. Immune stimulatory compositions are also provided, along with methods of their use.
    Type: Grant
    Filed: May 14, 2007
    Date of Patent: August 17, 2010
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Paul A. Rota, Larry J. Anderson, William J. Bellini, Michael D. Bowen, Cara Carthel Burns, Raymond Campagnoli, Qi Chen, James A. Comer, Byron T. Cook, Shannon L. Emery, Dean D. Erdman, Cynthia S. Goldsmith, Jeanette Guarner, Charles D. Humphrey, Joseph P. Icenogle, Thomas G. Ksiazek, Richard F. Meyer, Stephan S. Monroe, William Allan Nix, M. Steven Oberste, Christopher D. Paddock, Teresa C. T. Peret, Pierre E. Rollin, Mark A. Pallansch, Anthony Sanchez, Wun-Ju Shieh, Suxiang Tong, Sherif R. Zaki
  • Patent number: 7220852
    Abstract: Disclosed herein is a newly isolated human coronavirus (SARS-CoV), the causative agent of severe acute respiratory syndrome (SARS). Also provided are the nucleic acid sequence of the SARS-CoV genome and the amino acid sequences of the SARS-CoV open reading frames, as well as methods of using these molecules to detect a SARS-CoV and detect infections therewith. Immune stimulatory compositions are also provided, along with methods of their use.
    Type: Grant
    Filed: April 12, 2004
    Date of Patent: May 22, 2007
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Paul A. Rota, Larry J. Anderson, William J. Bellini, Cara Carthel Burns, Raymond Campagnoli, Qi Chen, James A. Comer, Shannon L. Emery, Dean D. Erdman, Cynthia S. Goldsmith, Charles D. Humphrey, Joseph P. Icenogle, Thomas G. Ksiazek, Stephan S. Monroe, William Allan Nix, M. Steven Oberste, Teresa C. T. Peret, Pierre E. Rollin, Mark A. Pallansch, Anthony Sanchez, Suxiang Tong, Sherif R. Zaki
  • Patent number: 6620913
    Abstract: The present invention relates to the discovery of a novel Hantavirus. In particular, the present invention relates to nucleic acids of the newly discovered virus and to nucleic acid reagents and antibodies for use in methods of detection and prevention of infection by the virus.
    Type: Grant
    Filed: April 18, 2002
    Date of Patent: September 16, 2003
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Stuart T. Nichol, Christina F. Spiropoulou, Thomas G. Ksiazek, Pierre E. Rollin
  • Patent number: 5945277
    Abstract: The present invention relates to the discovery of a novel Hantavirus. In particular, the present invention relates to nucleic acids of the newly discovered virus and to nucleic acid reagents and antibodies for use in methods of detection and prevention of infection by the virus.
    Type: Grant
    Filed: May 30, 1996
    Date of Patent: August 31, 1999
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Stuart T. Nichol, Christina F. Spiropoulou, Thomas G. Ksiazek, Pierre E. Rollin
  • Patent number: 5916754
    Abstract: The present invention relates to the discovery and isolation of a novel hantavirus designated the Bayou hantavirus. In particular, the present invention relates to nucleic acids of the newly discovered virus and to nucleic acid reagents (primers and probes), purified polypeptides and antibodies for use in methods of detection and prevention of infection by the virus. A vaccine or purified immunogenic polypeptide of the Bayou hantavirus in a pharmaceutically acceptable carrier is provided. A vector comprising the nucleic acids of the invention is provided. A method of detecting the presence of a hantavirus in a subject comprising contacting an antibody-containing sample from the subject with a purified polypeptide of the invention and detecting the reaction of the polypeptide and the antibody is provided.
    Type: Grant
    Filed: February 17, 1995
    Date of Patent: June 29, 1999
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Stuart T. Nichol, Sergey Morzunov, Thomas G. Ksiazek, Pierre E. Rollin, Christina F. Spiropoulou
  • Patent number: 5853980
    Abstract: The present invention relates to the discovery and isolation of a novel hantavirus designated the Black Creek Canal hantavirus. In particular, the present invention relates to nucleic acids of the newly discovered virus and to nucleic acid reagents (primers and probes), purified polypeptides and antibodies for use in methods of detection and prevention of infection by the virus. A vaccine or purified immunogenic polypeptide of the Black Creek Canal hantavirus in a pharmaceutically acceptable carrier is provided. A vector comprising the nucleic acids of the invention is provided. A method of detecting the presence of a hantavirus in a subject comprising contacting an antibody-containing sample from the subject with a purified polypeptide of the invention and detecting the reaction of the polypeptide and the antibody is provided.
    Type: Grant
    Filed: February 3, 1997
    Date of Patent: December 29, 1998
    Assignees: The United States of America as represented by the Department of Health and Human Services, National Institutes of Health Office of Technology Transfer
    Inventors: Pierre E. Rollin, Luanne Elliott, Thomas G. Ksiazek, Stuart T. Nichol, Sergey Morzunov, Eugeny Ravkov